At the end of the latest market close, BioCryst Pharmaceuticals Inc. (BCRX) was valued at $9.55. In that particular session, Stock kicked-off at the price of $9.60 while reaching the peak value of $9.73 and lowest value recorded on the day was $9.17. The stock current value is $9.20.
Recently in News on February 11, 2021, BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25. BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. You can read further details here
BioCryst Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $12.90 on 02/02/21, with the lowest value was $7.27 for the same time period, recorded on 01/05/21.
BioCryst Pharmaceuticals Inc. (BCRX) full year performance was 215.61%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, BioCryst Pharmaceuticals Inc. shares are logging -28.68% during the 52-week period from high price, and 482.28% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.58 and $12.90.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 5824369 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the BioCryst Pharmaceuticals Inc. (BCRX) recorded performance in the market was 23.49%, having the revenues showcasing 125.49% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.60B, as it employees total of 140 workers.
The Analysts eye on BioCryst Pharmaceuticals Inc. (BCRX)
During the last month, 0 analysts gave the BioCryst Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 6.10, with a change in the price was noted +5.19. In a similar fashion, BioCryst Pharmaceuticals Inc. posted a movement of +129.43% for the period of last 100 days, recording 6,784,678 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BCRX is recording 2.26 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.80.
Technical rundown of BioCryst Pharmaceuticals Inc. (BCRX)
Raw Stochastic average of BioCryst Pharmaceuticals Inc. in the period of last 50 days is set at 54.65%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 22.59%. In the last 20 days, the company’s Stochastic %K was 33.19% and its Stochastic %D was recorded 40.69%.
Considering, the past performance of BioCryst Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 23.49%. Additionally, trading for the stock in the period of the last six months notably improved by 131.74%, alongside a boost of 215.61% for the period of the last 12 months. The shares increased approximately by -4.66% in the 7-day charts and went down by 14.43% in the period of the last 30 days. Common stock shares were driven by 125.49% during last recorded quarter.